ATTD 2026: This 12-minute presentation explores perspectives on CGM use in prediabetes and type 2 diabetes.
This resource is intended for educational purposes only for healthcare providers practicing in the United States. It does not constitute medical advice and is not a substitute for professional judgment or individualized patient care.
In this 12-minute presentation, Dr. Viral Shah explores the value of early CGM adoption, discusses a staged approach to prediabetes and T2D, and highlights how CGM can help address clinical inertia and support earlier interventions.
This presentation is part of the Transforming Diabetes Care:The Power of Dexcom CGM from Prediabetes to Insulin Therapy session, recorded live at Advanced Technologies & Treatments for Diabetes (ATTD) 2026 in Barcelona, Spain on March 13, 2026.
Watch additional presentations from Transforming Diabetes Care:The Power of Dexcom CGM from Prediabetes to Insulin Therapy session, recorded live at Advanced Technologies & Treatments for Diabetes (ATTD) 2026.
This is a recording of a live presentation. The information you see or hear at this event provides details about medical products which are not available in all countries, may have different indications, and/or have not received approval or market clearance by all governmental regulatory bodies throughout the world. Nothing shown or stated herein should be construed as a solicitation, advertisement, or promotion of any product, or of an indication of any specific use for any product, which is not authorized by the laws and regulations of the country where you reside. The content may include the presenter’s own experience sharing and data – please do not record or distribute the presentation slides.
